Southpoint Capital Advisors’s Fennec Pharmaceuticals FENC Stock Holding History

Southpoint Capital Advisors’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,744,741	Closed	-$16.9M	–	39
2026 Q1	$16.9M	Hold	2,744,741	–	–	0.35%	37
2025 Q4	$21.1M	Sell	2,744,741 -1,332,473	-33%	-$10.9M	0.49%	35
2025 Q3	$38.2M	Hold	4,077,214	–	–	1%	28
2025 Q2	$33.8M	Hold	4,077,214	–	–	0.85%	31
2025 Q1	$24.8M	Hold	4,077,214	–	–	0.59%	38
2024 Q4	$25.8M	Hold	4,077,214	–	–	0.6%	36
2024 Q3	$20.4M	Hold	4,077,214	–	–	0.48%	38
2024 Q2	$24.9M	Hold	4,077,214	–	–	0.62%	37
2024 Q1	$45.3M	Hold	4,077,214	–	–	0.9%	37
2023 Q4	$45.7M	Hold	4,077,214	–	–	0.98%	32
2023 Q3	$30.6M	Hold	4,077,214	–	–	0.68%	38
2023 Q2	$36M	Hold	4,077,214	–	–	0.78%	35
2023 Q1	$33.9M	Hold	4,077,214	–	–	0.77%	38
2022 Q4	$39.1M	Hold	4,077,214	–	–	1.01%	26
2022 Q3	$33M	Hold	4,077,214	–	–	0.89%	30
2022 Q2	$22.8M	Hold	4,077,214	–	–	0.65%	32
2022 Q1	$22.8M	Hold	4,077,214	–	–	0.44%	41
2021 Q4	$17.9M	Hold	4,077,214	–	–	0.34%	44
2021 Q3	$38.4M	Hold	4,077,214	–	–	0.82%	33
2021 Q2	$29.7M	Hold	4,077,214	–	–	0.52%	41
2021 Q1	$25.3M	Hold	4,077,214	–	–	0.41%	48
2020 Q4	$30.4M	Hold	4,077,214	–	–	0.53%	35
2020 Q3	$24.7M	Hold	4,077,214	–	–	0.56%	34
2020 Q2	$34M	Buy	4,077,214 +80,000	+2%	+$595K	0.83%	34
2020 Q1	$23.7M	Hold	3,997,214	–	–	0.69%	30
2019 Q4	$25.9M	Hold	3,997,214	–	–	0.93%	25
2019 Q3	$19.2M	Hold	3,997,214	–	–	0.73%	26
2019 Q2	$16M	Hold	3,997,214	–	–	0.6%	28
2019 Q1	$19.4M	Hold	3,997,214	–	–	0.82%	26
2018 Q4	$25.5M	Hold	3,997,214	–	–	1.23%	24
2018 Q3	$32.8M	Hold	3,997,214	–	–	1.27%	25
2018 Q2	$41.7M	Hold	3,997,214	–	–	1.77%	21
2018 Q1	$48.3M	Hold	3,997,214	–	–	2.14%	20
2017 Q4	$40.1M	Hold	3,997,214	–	–	1.91%	26
2017 Q3	$44.3M	Buy	+3,997,214	New	+$46.4M	1.82%	19

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Southpoint Capital Advisors's FENC Position: Q2 2026 in Review

Southpoint Capital Advisors sold out of Fennec Pharmaceuticals (FENC) in Q2 2026, closing a stake of 2,744,741 shares — an estimated $16.9M sold.

Southpoint Capital Advisors first reported a position in FENC in Q3 2017 and held it in 35 quarters. The position peaked at $48.3M in Q1 2018. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

Southpoint Capital Advisors reported no remaining Fennec Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Southpoint Capital Advisors sold 2,744,741 Fennec Pharmaceuticals shares in Q2 2026, an estimated $16.9M.
Southpoint Capital Advisors first reported a position in Fennec Pharmaceuticals in Q3 2017 and held it in 35 quarters.
Southpoint Capital Advisors's Fennec Pharmaceuticals position peaked at $48.3M in Q1 2018.
105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Southpoint Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.